SPDB-DM4 represents an linker-payload in which the maytansine-derived payload DM4, known for its tubulin-inhibiting properties, is linked via an SPDB linker, resulting in a highly effective treatment with strong anti-tumor capabilities. It is suitable to be conjugated into antibody drug conjugates (ADCs).
Usually ships within 24 hours.